DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Nintedanib
Nintedanib
Prescription Drugs Requiring Prior Authorization
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
CELEBRATING 25 YEARS of PROGRESS for PATIENTS for PROGRESS of YEARS 25 CELEBRATING Annual Report 2019 Report Annual
Inhibition of Mast Cells: a Novel Mechanism by Which Nintedanib
Your Pharmacy Benefits Welcome to Your Pharmacy Plan
Australian Public Assessment Report for Nintedanib Esilate
Nintedanib (OFEV) Information for Patients
Phase II Trial of Nintedanib in Patients with Advanced Esophagogastric Cancer PROTOCOL FACE PAGE for MSKCC THERAPEUTIC/DIAGNOSTIC PROTOCOL
Use of Multitarget Tyrosine Kinase Inhibitors to Attenuate Platelet-Derived Growth Factor Signalling in Lung Disease
Nintedanib Ameliorates Experimental Pulmonary Arterial
HIGHLIGHTS of PRESCRIBING INFORMATION Thereafter Or As Clinically Indicated
Lorlatinib (PF-06463922) for Advanced ALK Or ROS1 Positive Non-Small Cell Lung Cancer – Second Line NIHRIO (HSRIC) ID: 14896 NICE ID: 9656
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
Gilteritinib Overcomes Lorlatinib Resistance in ALK-Rearranged Cancer
Potential Therapeutic Implication for Synovial Sarcoma Parag P
Drug-Induced Interstitial Lung Disease in Breast Cancer Patients: a Lesson We Should Learn from Multi-Disciplinary Integration
Trastuzumab Deruxtecan for HER2 Mutant Unresectable And/Or Metastatic Non-Squamous Non-Small Cell Lung Cancer – Second Line
Nintedanib for Previously Treated Locally Advanced, Metastatic, Or Locally Recurrent Non-Small-Cell Lung Cancer
Top View
Augmentation of Nab-Paclitaxel Chemotherapy Response By
CHMP Assessment Report
Nintedanib (OFEV®)
Nintedanib: a Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Nintedanib: Drug Information
Medicaid List of Covered Drugs (Formulary)
Summary of Risk Management Plan for Vargatef (Nintedanib)
The Interactions of Nintedanib and Oral Anticoagulants—Molecular Mechanisms and Clinical Implications
Angiokinase Inhibitors in Non-Small-Cell Lung Cancer
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Ofev, INN-Nintedanib
Ez-Minutes February-April 2013
Computationally Predicting Clinical Drug Combination Efficacy With
Efficacy of First Line Systemic Chemotherapy And
Supplementary Appendix
WHO Drug Information Vol
Comparisons of Non-Small Cell Lung Cancer Treatment Options: New Zealand and Australia Versus European Society for Medical Oncology (ESMO) Guidelines
Proposal for Funding of Oncology, Multiple Sclerosis and Respiratory Treatments 7 August 2019
Specialty Pipeline MONTHLY UPDATE
Second-Line Treatment for Advanced NSCLC Without Actionable Mutations: Is Immunotherapy the ‘Panacea’ for All Patients? Alessandro Morabito
Emerging Multitarget Tyrosine Kinase Inhibitors in the Treatment of Neuroendocrine Neoplasms
Non-Small Cell Lung Cancer Targetable Mutations: Present and Future
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage Via Blocking Oncogenic Receptor Tyrosine Kinases S
The Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage Via Blocking Oncogenic Receptor Tyrosine Kinases
Mode of Action of Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis
Ninetedanib (OFEV) National Drug Monograph March 2015
Therapeutic Sequencing in ALK+ NSCLC
To Quantify the Small-Molecule Kinase Inhibitors Ceritinib, Dacomitinib
205832Orig1s000
CVS Caremark® Value Formulary Effective As of 07/01/2021
Specialty Pipeline MONTHLY UPDATE
Targeting Angiogenesis: Vascular Endothelial Growth Factor and Related Signaling Pathways
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
205832Orig1s000
Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
Anti-Fibrotic Efficacy of Nintedanib in Pulmonary Fibrosis Via the Inhibition
Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines
Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases
Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: a Perspective
In the Treatment of Early Diffuse Systemic Sclerosis: an Open-Label, Pilot Clinical Trial Jessica K
1 Nintedanib Targets KIT D816V Neoplastic Cells Derived
Mir-200/ZEB Axis Regulates Sensitivity to Nintedanib in Non-Small Cell Lung Cancer Cells
Therapeutic Drug Class
Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
Publication Agenda CHMP 07-10 December 2020
Repurposing Nintedanib for Pathological Cardiac Remodeling and Dysfunction
The Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage Via Blocking Oncogenic Receptor Tyrosine Kinases
2019 Prior Authorization Criteria
New Insights Into the Pathogenesis of Systemic Mastocytosis
Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of The
Tyrosine Kinase Receptors in Oncology
1 Nintedanib Targets KIT D816V Neoplastic Cells Derived From